These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20596679)

  • 1. Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation.
    Shiota M; Eto M; Yokomizo A; Tada Y; Takeuchi A; Itsumi M; Tatsugami K; Uchiumi T; Naito S
    Int J Oncol; 2010 Aug; 37(2):509-17. PubMed ID: 20596679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition.
    Shiota M; Eto M; Yokomizo A; Tada Y; Takeuchi A; Masubuchi D; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Seki N; Naito S
    Int J Oncol; 2010 Jun; 36(6):1521-31. PubMed ID: 20428777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.
    Rahmani M; Davis EM; Crabtree TR; Habibi JR; Nguyen TK; Dent P; Grant S
    Mol Cell Biol; 2007 Aug; 27(15):5499-513. PubMed ID: 17548474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
    Park MA; Zhang G; Martin AP; Hamed H; Mitchell C; Hylemon PB; Graf M; Rahmani M; Ryan K; Liu X; Spiegel S; Norris J; Fisher PB; Grant S; Dent P
    Cancer Biol Ther; 2008 Oct; 7(10):1648-62. PubMed ID: 18787411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
    Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W
    J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
    Richly H; Kupsch P; Passage K; Grubert M; Hilger RA; Kredtke S; Voliotis D; Scheulen ME; Seeber S; Strumberg D
    Int J Clin Pharmacol Ther; 2003 Dec; 41(12):620-1. PubMed ID: 14692720
    [No Abstract]   [Full Text] [Related]  

  • 7. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
    Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.
    Zhang Z; Zhou X; Shen H; Wang D; Wang Y
    BMC Med; 2009 Aug; 7():41. PubMed ID: 19698189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.
    Hoffmann K; Franz C; Xiao Z; Mohr E; Serba S; Büchler MW; Schemmer P
    Anticancer Res; 2010 Nov; 30(11):4503-8. PubMed ID: 21115899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.
    Zou W; Bai Y; Wang X; Cheng K; Sun H; Zhang G; Wang X; Yang Z
    Cancer Biother Radiopharm; 2017 Oct; 32(8):282-287. PubMed ID: 29053414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.
    Inoue H; Hwang SH; Wecksler AT; Hammock BD; Weiss RH
    Cancer Biol Ther; 2011 Nov; 12(9):827-36. PubMed ID: 21878748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Bareford MD; Park MA; Yacoub A; Hamed HA; Tang Y; Cruickshanks N; Eulitt P; Hubbard N; Tye G; Burow ME; Fisher PB; Moran RG; Nephew KP; Grant S; Dent P
    Cancer Res; 2011 Jul; 71(14):4955-67. PubMed ID: 21622715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.
    Kharaziha P; Rodriguez P; Li Q; Rundqvist H; Björklund AC; Augsten M; Ullén A; Egevad L; Wiklund P; Nilsson S; Kroemer G; Grander D; Panaretakis T
    Cell Death Dis; 2012 Jan; 3(1):e262. PubMed ID: 22278289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
    Chen G; Nicula D; Renko K; Derwahl M
    Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
    PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells.
    Adjibade P; St-Sauveur VG; Quevillon Huberdeau M; Fournier MJ; Savard A; Coudert L; Khandjian EW; Mazroui R
    Oncotarget; 2015 Dec; 6(41):43927-43. PubMed ID: 26556863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.